Shionogi Co & Ltd is one of Japan’s leading research based pharmaceutical companies with the sales of 289, 717 million yen (approx.  £1,665 million / £=174 yen) in 2013.

Their mission is “to provide medicine of the best possible quality essential for the protection of peoples’ health”.  They are engaged in R&D, manufacturing and marketing activities with a primary focus on prescription drugs, OTC and diagnostics.  For the R&D, they have designated Obesity/Diabetes and Viral Infection as priority areas. Shionogi’s ethical pharmaceutical business is their core which accounts for over 90% of total sales.  Their core therapeutic areas are metabolic syndrome, pain and infectious diseases.   Their core products include Crestor (cholesterol medication), the Irbetan family of drugs (Irbetan and Aimix: anti-hypertension drug), Cymbalta (depression treatment) to name just a few.

Shionogi is currently looking to expand their global business network.  The acquisition of an American firm Sciele Pharma Inc in 2008 has expanded their product portfolio as well as established sales infrastructure in the US market.

In Europe, they established Shionogi Ltd in London in 2012 as a development centre for accelerating commercialisation of pipeline products.  Their key objectives are to promote the SHIONOGI Science Programme, an industry-academic collaboration programme focusing on joint research, as well as furthering Shionogi’s development on a global scale by careful selection of distribution partners.

For more information, please visit the company website at www.shionogi.co.jp/en .

This free webinar will give an overview of Shionogi’s business and partnering strategy with particular focus on areas of potential collaboration with UK businesses. It will also touch on the application process for SHIONOGI Science Programme.